2023 World Conference on Lung Cancer (Posters)-EP11.03. Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small-Cell Lung Cancer

EP11.03. Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small-Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study conducted at the Guangzhou Chest Hospital in China aimed to investigate the efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in patients with advanced non-small-cell lung cancer (NSCLC). The study included 24 patients who were treated with this combination therapy. The main outcome measures were progression-free survival (PFS) and objective response rate (ORR), while the secondary outcome measures were disease control rate (DCR) and adverse events (AEs).<br /><br />The results showed that at a median follow-up of 20 months, the median PFS was 11 months. Patients who received first-line treatment achieved a median PFS of 11 months, with 6-month and 12-month PFS rates of 82.4% and 52.9% respectively. The first-line treatment also resulted in an ORR of 58.8% and a DCR of 94.1%. <br /><br />Grade 3-4 treatment-related adverse events, mostly hematotoxicity, occurred in 11.8% of patients. Grade 1-2 treatment-mediated adverse events were observed in 47.1% of patients, with hematotoxicity, pruritus, and hepatic toxicity being the most common.<br /><br />In conclusion, chemotherapy plus immunotherapy and recombinant human endostatin showed promising efficacy with a manageable safety profile in patients with advanced NSCLC. These findings suggest that this combination therapy could be an effective treatment option for patients with this type of lung cancer.<br /><br />Keywords: lung cancer, chemotherapy, immunotherapy, recombinant human endostatin.

Asset Subtitle

Shan Su

Meta Tag

Speaker Shan Su

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

lung cancer

chemotherapy

immunotherapy

recombinant human endostatin

efficacy

safety

non-small-cell lung cancer

progression-free survival

objective response rate

disease control rate